|Home | About | Journals | Submit | Contact Us | Français|
Bile salt–dependent lipase (BSDL) is an enzyme involved in the duodenal hydrolysis and absorption of cholesteryl esters. Although some BSDL is transported to blood, the role of circulating BSDL is unknown. Here, we demonstrate that BSDL is stored in platelets and released upon platelet activation. Because BSDL contains a region that is structurally homologous to the V3 loop of HIV-1, which binds to CXC chemokine receptor 4 (CXCR4), we hypothesized that BSDL might bind to CXCR4 present on platelets. In human platelets in vitro, both BSDL and a peptide corresponding to its V3-like loop induced calcium mobilization and enhanced thrombin-mediated platelet aggregation, spreading, and activated αIIbβ3 levels. These effects were abolished by CXCR4 inhibition. BSDL also increased the production of prostacyclin by human endothelial cells. In a mouse thrombosis model, BSDL accumulated at sites of vessel wall injury. When CXCR4 was antagonized, the accumulation of BSDL was inhibited and thrombus size was reduced. In BSDL–/– mice, calcium mobilization in platelets and thrombus formation were attenuated and tail bleeding times were increased in comparison with those of wild-type mice. We conclude that BSDL plays a role in optimal platelet activation and thrombus formation by interacting with CXCR4 on platelets.
Pancreatic cholesterol esterase or bile salt–dependent lipase (BSDL; E.C.126.96.36.199) is an enzyme involved in the duodenal hydrolysis and absorption of cholesteryl esters (1, 2). BSDL is synthesized in the endoplasmic reticulum of pancreatic acinar cells and follows the secretion pathway to the duodenal lumen (3). The enzyme, which is N- and O-glycosylated (4, 5), is found in pancreatic secretions of all vertebrates examined to date. To generate significant lipase activity, BSDL must interact with bile salts in the duodenal lumen. Once activated, BSDL, in concert with other digestive lipolytic enzymes, degrades dietary lipids and participates in the hydrolysis of cholesterol esters into free cholesterol and fatty acids (6). In the duodenum, a fraction of BSDL is internalized by enterocytes via the lectin-like oxidized LDL receptor (LOX-1) and transported to the blood compartment (7, 8), where it partly associates with apolipoprotein B–containing lipoproteins in plasma (6). The concentration of circulating BSDL in human serum, determined by ELISA using polyclonal antibodies, is 1.5 ± 0.5 μg/l (9–11) but is elevated to a level as high as 7 μg/l in some pathological conditions, such as acute pancreatitis (12). BSDL has also been detected in human aortic homogenate and in atherosclerotic lesions of hypercholesterolemic monkeys and of human arteries (13). This enzyme is also found in the vessel wall homogenate (14). Although there are conflicting reports, the enzyme may be synthesized by macrophages and endothelial cells (14, 15). Alternatively, BSDL, which has a heparin-binding site (16) and a V3-like loop domain (17), associates with intestinal cell-surface proteoglycans (7, 8). In vitro studies have shown that BSDL induces vascular smooth muscle cell proliferation and evokes endothelial cell proliferation and chemotactic migration (13, 18). However, the function of circulating plasma pancreatic BSDL is still unknown.
Platelets, in addition to their role in hemostasis, are involved in inflammation, immunological reactions, and atherosclerosis. Platelets contain both chemokine receptors expressed at their surfaces and chemokines, such as RANTES and MIP-1, stored in platelet granules and released upon platelet activation (19, 20). In particular macrophage-derived chemokine (MDC), which is not present in platelet granules, and stromal cell–derived factor–1 (SDF-1), which may be present in platelet granules (19, 21), have been described as platelet agonists by interacting with CCR4 and CXCR4, respectively. SDF-1 binding to CXCR4 induces intracellular calcium mobilization in platelets and increases platelet aggregation induced by thrombin or ADP (22, 23). The ability of chemokines to stimulate platelets is dependent upon the presence of platelet agonists such as ADP or thrombin (24). Furthermore, chemokine-induced platelet aggregation is inhibited by aspirin, suggesting involvement of thromboxane A2 in this response (25).
CXCR4 interacts with the V3 loop of the 120-kDa glycoprotein (gp120) from HIV-1 (26). Since BSDL contains a structure homologous to this V3 loop, called the V3-like loop domain (17) (amino acid residues N361 to L393; Table Table1),1), we explored the interaction of circulating BSDL with the platelet CXCR4 receptor. We have determined that BSDL is stored in platelets and released upon platelet activation. Furthermore, circulating BSDL and/or BSDL released from platelets play a significant synergistic role in optimal platelet activation and thrombus formation through its action on platelet CXCR4.
SDF-1, a known CXCR4 ligand, does not induce platelet aggregation by itself but increases platelet aggregation induced by thrombin or ADP (Table (Table2)2) (23). We determined whether human BSDL (hBSDL), with its V3-like loop, can modulate platelet aggregation induced by different agonists. Purified hBSDL (27) had no effect on resting platelets. However the presence of BSDL significantly enhanced activation of platelets by suboptimal concentrations of thrombin (Figure (Figure1,1, A and B). A similar effect of hBSDL was observed using 2.5 μM ADP and Par1 and Par4 agonist peptides SFLLRN (thrombin receptor activation peptide–1 [TRAP-1] at 10 μM) and AYPGKF (TRAP-4 at 100 μM) in place of thrombin (Table (Table2).2). At 0.8 U/ml of thrombin, a 5% increase in aggregation was observed when BSDL was included (Figure (Figure1A,1A, right panel). At 0.5 U/ml of thrombin, a 15% increase in aggregation was observed with hBSDL (Figure (Figure1A,1A, middle panel). At 0.1 U/ml of thrombin, a 75% increase was observed in the presence of hBSDL (Figure (Figure1A,1A, left panel, and Figure Figure1B).1B). The effect of BSDL on thrombin-induced platelet aggregation was blocked by the inhibitory antibody against CXCR4, 12G5, thus indicating a role for CXCR4 in this process. To determine whether hBSDL augments thrombin-induced platelet aggregation through interaction between its V3-like loop and CXCR4 on platelets, we performed experiments using V3-like loop peptides (Table (Table1),1), CXCR4-blocking antibodies (clone 12G5 and clone 44716.111), or a specific CXCR4 antagonist (AMD3100) (28). Addition of 1 μg of V3-like loop domain peptide (Table (Table1,1, V3) to thrombin-activated platelets augmented aggregation similarly to hBSDL (Figure (Figure1B).1B). In contrast, a V3-like loop peptide mutated at amino acids involved in the salt bridge or with a scrambled sequence (Table (Table1,1, V3LSal, V3Lscr) did not increase platelet aggregation (Figure (Figure1B).1B). In the presence of CXCR4-blocking antibodies (12G5) (Figure (Figure1A)1A) or the CXCR4 antagonist, but not in the presence of irrelevant control antibody (data not shown), BSDL and the V3-like loop peptide had no effect on thrombin-induced platelet aggregation (Figure (Figure1B). 1B).
hBSDL also influences platelet spreading. Although BSDL had no effect on resting human platelets, it increased the spreading of thrombin-activated platelets on a glass coverslip after 20 and 40 minutes (Figure (Figure2,2, A and B). Platelet aggregation and spreading are both mediated by intracellular signaling, converging on the activation of the integrin αIIbβ3. The extent of αΙΙbβ3 activation in thrombin-activated platelets significantly increased in the presence of hBSDL (Figure (Figure2C),2C), but there was no effect of hBSDL on P selectin surface expression of thrombin-activated platelets (data not shown). Thus, hBSDL does not increase the magnitude of degranulation but only the magnitude of αIIbβ3 activation. Addition of the V3-like loop domain peptide also augmented thrombin-induced αIIbβ3 activation, but the mutated V3-like loop domain peptide and the scrambled V3-like peptide did not (Figure (Figure2C).2C). The effects of BSDL or V3 peptide were blocked when platelets were treated with 1 mM aspirin (data not shown), suggesting that production of thromboxane A2 plays a key role in the intracellular pathways induced by BSDL on platelets.
Previous reports have shown that the binding of SDF-1 to platelet CXCR4 induces calcium mobilization (25). We demonstrated that BSDL and the V3 loop peptide had a similar effect. When platelets were challenged with 0.5 μg BSDL or with 0.1 μg V3-like loop peptide, intracellular calcium was mobilized, as measured using fura-2. This calcium rise was blocked when CXCR4 was inhibited with the anti-CXCR4 antibody 12G5 (Figure (Figure2D).2D). These results indicate that purified hBSDL or the V3-like loop peptide act on CXCR4 to induce calcium mobilization, to enhance αIIbβ3 activation, to augment platelet aggregation, and to increase platelet spreading induced by thrombin.
To understand the mechanisms involved in the action of BSDL on activated platelets, we determined whether platelets contain or express BSDL. We observed that washed platelet lysates prepared from different individuals all specifically reacted by Western blotting at the same molecular mass as human purified BSDL (115 kDa) with the antibody pAbL32 directed against hBSDL (Figure (Figure3A).3A). Similar results were observed with the anti-BSDL antibody pAbL64 (data not shown). When platelets were activated with 0.1 U/ml thrombin and washed before lysis, the quantity of BSDL contained within platelets decreased in comparison with that in resting platelets (Figure (Figure3B).3B). As a control, we verified that the quantity of protein loaded before and after platelet activation was identical (42 μg of protein loaded in each well). These results were confirmed by FACS analysis. The signal corresponding to BSDL was increased in resting permeabilized platelets in comparison with nonpermeabilized or activated platelets (Figure (Figure3C).3C). The quantity of BSDL present in platelets was estimated by Western blot analysis as 6,000 molecules of BSDL per platelet. Kowalska et al. have previously estimated the quantity of CXCR4 expressed on resting human platelets as 2,600 receptors per platelet (22). We observed by immunofluorescence that the quantity of CXCR4 present on the platelet membrane increased following platelet activation by 0.1 U/ml thrombin (Figure (Figure3D).3D). Together, these results indicate that upon thrombin activation, platelets exposed more CXCR4 receptors at their surface. This would explain why BSDL and SDF-1 mainly act on activated platelets.
To determine whether BSDL might play a physiological role in platelet aggregation and thrombus formation, we studied the biology of BSDL within the context of thrombus formation in a live mouse. We have previously described an in vivo model of thrombosis using intravital high-speed confocal and wide-field multichannel digital microscopy, which allows the detection in real time of fluorescence signals at the site of laser-induced injury in mice (29). Using polyclonal anti-hBSDL antibodies, pAbL32 and pAbL64, and pAbantipeptide (30), all cross-reactive with mouse BSDL (mBSDL), we determined that endogenous mBSDL accumulates in arterial thrombi in vivo following laser-induced vessel wall injury (31). Endogenous mBSDL accumulation at the site of injury could be detected using any of the 3 polyclonal antibodies. A representative example using pAbantipeptide is shown in Figure Figure4A.4A. The median accumulation of the fluorescence signal corresponding to an antibody directed against endogenous BSDL (26 thrombi in 3 wild-type mice) versus an irrelevant antibody (36 thrombi in 3 wild-type mice) over time is shown in Figure Figure4B.4B. BSDL-reactive antibodies, but not irrelevant antibody, were detected immediately after laser injury, and its signal increased over time in parallel with the developing thrombus. The same kinetics of BSDL accumulation were observed when polyclonal antibodies pAbL32 or pAbL64 were infused into the circulation of wild-type mice (32 thrombi in 3 mice for each antibody) with differences in the maximum integrated fluorescence intensity of the 2 antibodies (Figure (Figure4C).4C). These results indicate that following laser-induced injury, endogenous BSDL accumulates at the site of injury. Confocal intravital microscopy in real time was performed to localize endogenous BSDL relative to platelets within a developing thrombus (Figure (Figure4D).4D). Platelets were identified with fluorescently labeled Fab fragments derived from a monoclonal anti-CD41 antibody as previously described (32). Endogenous mBSDL (green) and platelets (red) colocalized (merge, yellow) in a focal plane through the approximate center of the thrombus, indicating that BSDL interacts with the vessel wall and platelets participating in a developing thrombus in vivo. Endothelial cells such as HUVECs have been previously described to express CXCR4 on their surfaces, and this expression could be increased following activation of endothelial cells (33). In vitro, hBSDL did not affect the production of nitric oxide (Figure (Figure5A).5A). However, the enzyme significantly increased HUVEC production of prostacyclin in a dose-dependent manner following treatment with 0.1 U/ml thrombin (Figure (Figure5B).5B). These results suggest that BSDL could also participate in the in vivo activation of the injured endothelium.
The participation of BSDL in thrombus formation after laser injury was confirmed by studying thrombus formation in BSDL-null mice (34). As anticipated, no BSDL could be detected accumulating in the thrombus of BSDL-null mice (Figure (Figure6A).6A). The kinetics of platelet accumulation in wild-type mice and BSDL-null mice were compared (Figure (Figure6B).6B). By studying 30 thrombi and determining the median values as a function of time, we observed that while the kinetics of thrombus growth were similar in the 2 genotypes, thrombus size was reduced in BSDL-null mice in comparison with wild-type mice (Figure (Figure6C).6C). Peak platelet accumulation was reduced 50% in BSDL-null mice in comparison with wild-type mice (Figure (Figure6D).6D). When the maximal fluorescence intensities corresponding to platelet accumulation for each thrombus in BSDL-null (n = 36, 3 mice) and wild-type mice (n = 32, 3 mice) were ranked in order of increasing thrombus size and compared using quartile analysis, we observed that 8% of thrombi in BSDL-null mice but 47% of thrombi in wild-type mice constituted the largest thrombi (Figure (Figure6E).6E). These results confirm that maximal thrombus size was reduced in BSDL-null mice. However, there were no significant differences in the median time to maximum platelet accumulation after laser-induced injury between the 2 mouse genotypes (data not shown). These results suggest that BSDL enhances the activation and aggregation of platelets in vivo.
To confirm the involvement of endogenous BSDL in optimal thrombus formation, we examined tail vein bleeding time as a method of monitoring the kinetics of thrombus formation. The median tail vein bleeding time observed for BSDL-null mice was 395 seconds (n = 10), significantly higher than the 120-second median tail vein bleeding time for wild-type mice (n = 10) (Figure (Figure7A).7A). Together these in vivo results indicate that BSDL plays a role in optimal thrombus formation.
We have previously shown that thrombin is the major platelet agonist involved in thrombus formation following laser-induced injury under our conditions (35). To exclude the possibility that thrombin generation was defective in BSDL-null mice in comparison with wild-type mice, fibrin accumulation at the site of injury was compared in BSDL-null and wild-type mice. No differences were observed in fibrin generation at the site of laser-induced injury in BSDL-null (n = 28, 3 mice) and wild-type mice (n = 30, 3 mice) (Figure (Figure7B).7B). We conclude that BSDL plays a role in vivo in platelet thrombus growth without affecting thrombin generation.
We have recently described a method to monitor in vivo calcium mobilization in fura-2–loaded platelets participating in the development of a thrombus (36, 37). This method was used to compare in vivo platelet activation in BSDL-null mice and wild-type mice. Fura-2–loaded platelets (250 × 106 to 300 × 106) prepared from BSDL-null or wild-type mice were infused into the circulation of a donor mouse of the same genotype. Fura-2–loaded platelets were detected after excitation at 380 nm and emission at 510 nm. Calcium mobilization into these platelets was detected after excitation at 340 nm and emission at 510 nm as previously described (38). Whereas fura-2–loaded platelets (green) rapidly accumulated at the site of laser injury, calcium mobilization (in yellow) was reduced in BSDL-null mice in comparison with wild-type mice (Figure (Figure8A).8A). As previously observed by infusing antibodies directed against CD41, the maximal size of the thrombus was also reduced in the BSDL-null mice in comparison with the wild-type mice (Figure (Figure8,8, A and B). Platelet activation was quantitated by analysis of the median fluorescence associated with calcium mobilization in multiple thrombi in wild-type (n = 18, 3 mice) and BSDL-null mice (n = 18, 3 mice) (Figure (Figure8,8, B and C). To correct the magnitude of platelet activation for the decreased accumulation of platelets observed in BSDL-null mice compared with wild-type mice (Figure (Figure8B),8B), the mean integrated fluorescence associated with activated platelets was compared with the mean integrated fluorescence associated with the total platelets accumulated within the thrombus (Figure (Figure8C).8C). In this analysis, platelet activation, as measured by the ratio of fluorescence associated with activated platelets to the fluorescence associated with total platelets, was diminished by 50% in BSDL-null mice in comparison with wild-type mice. These results indicate that although fibrin generation is equivalent in BSDL-null mice and wild-type mice, activation of BSDL-null platelets is defective in this in vivo model. These results indicate that in vivo blood BSDL plays a role in platelet activation leading to optimal thrombus formation.
Our in vitro results indicate that purified BSDL interacts with CXCR4 on human platelets. To determine whether in vivo endogenous mBSDL is involved in optimal platelet activation by interacting with CXCR4 on platelet and endothelial cells, we compared the kinetics of endogenous mBSDL and platelet accumulation in wild-type mice in the presence of the CXCR4 antagonist AMD3100 or in the presence of the vehicle alone (28). The specific CXCR4 antagonist AMD3100 prevented the binding of endogenous BSDL and markedly reduced accumulation of platelets at the site of laser injury (Figure (Figure9,9, A and B), confirming that the interaction of BSDL with CXCR4 on platelets and the endothelium impacts thrombus formation in vivo.
Blood coagulation is a host defense mechanism that maintains the closed circulatory system when blood vessel integrity is compromised. Pathological processes such as inflammation and atherosclerosis are associated with thrombosis. Thrombosis is also a major complication in gastrointestinal adenocarcinoma, particularly pancreatic carcinoma (39). In addition to BSDL, pancreatic carcinoma cells express high levels of an oncofetal variant of the enzyme, the fetoacinar pancreatic protein (FAPP) (40, 41), missing 10 of 16 proline-rich repeats at the C-terminal end of the protein but containing the V3-like loop region (42). This protein is found at elevated levels in most patients with pancreatic cancer (40). We thus sought to define the role of circulating BSDL.
In this study we demonstrate that BSDL plays a physiological role in thrombus formation, a unique function for a lipase. Our in vitro results indicate that BSDL, by increasing the amount of activated αIIbβ3, enhances both the aggregation and the spreading of thrombin-activated platelets. The enzyme also induces calcium mobilization, a marker of platelet activation. The V3-like loop structure of BSDL mimics these effects through interaction with the chemokine receptor CXCR4. In vivo, we show that BSDL accumulates in a CXCR4-dependent interaction on platelets at the site of laser-induced injury, enhancing platelet accumulation. These results indicate that BSDL acts as a chemokine to optimize platelet aggregation and platelet thrombus formation.
There have been several studies on the effects of chemokines on platelets in vitro (19, 20, 24). Based on the action of SDF-1 on platelets, some chemokines have been defined as weak platelet agonists (25) because of the increased platelet aggregation induced by thrombin or ADP after chemokine stimulation. Furthermore Clemetson et al. (19) have shown that SDF-1 induces intracellular calcium mobilization in platelets. These effects are prevented when the production of thromboxane A2 is inhibited by aspirin. In the present study, we observed that BSDL or a peptide with sequence homology to its V3-like loop induces calcium mobilization and increases platelet aggregation and αIIbβ3 activation in thrombin-activated platelets. These effects were prevented using either blocking antibodies or a specific inhibitor (AMD3100) against CXCR4 or aspirin to prevent the generation of thomboxane A2. Based on our results and those described for chemokines (25), we conclude that BSDL acts as a chemokine on platelets.
Two studies have previously determined the concentration of circulating BSDL in serum at 1.5 ± 0.5 μg/l (9, 11). We have previously shown that BSDL is found in the circulation both free and bound to apolipoprotein B–containing lipoproteins (7). Further analysis of the original data allowed us to calculate the distribution of free BSDL versus BSDL bound to apolipoprotein B–containing lipoproteins bound BSD. We determined that 35% ± 7% of the total circulating BSDL was found free in plasma versus 57% ± 7% bound to apolipoprotein B–containing lipoproteins (VLDL, LDL, and chylomicrons). However, we present here evidence that BSDL is also detectable in platelets and released into the blood circulation upon activation. It is then possible that the quantity of local BSDL increases greatly during the formation of a platelet thrombus. This explains why we can detect endogenous BSDL at sites of laser-induced injury (Figure (Figure3).3). Therefore, we conclude that in vivo, the local concentration of BSDL at the sites of injury is much higher than the concentration of circulating BSDL in blood. Although some BSDL is associated with platelets within the thrombus, some also concentrates on the vessel wall. Since in vitro studies have shown that BSDL can interact with activated endothelial cells to promote wound healing, we determined whether BSDL could modify the prostacyclin and nitric oxide production of HUVECs in vitro. Our results showed that indeed BSDL increases the production of prostacyclin by thrombin-treated HUVECs. This may explain why in vivo a fraction of detected BSDL was interacting with (activated) endothelium at the site of the injured vessel (see Figure Figure4D). 4D).
BSDL may play a role in cancer-associated thrombosis. Even if a direct link between an increase in circulating BSDL (or BSDL stored in platelets) and a prothrombotic tendency is to date not known, pancreatic carcinoma is associated with a prothrombotic state (43). Furthermore, our laboratory has identified the protein FAPP as an oncofetal isoform of BSDL (40). Last, the concentration of circulating BSDL (including FAPP) is enhanced during the development of a pancreatic cancer (41). Together these results may identify BSDL and FAPP as important agents linking thrombosis to pancreatic carcinoma. These results may also suggest a role for the V3 loop of gp120 in thrombosis associated with HIV-1 infection (26). Further, we conclude that BSDL interaction with CXCR4 may be a new target for antithrombotic therapy in these and other disease states.
Wild-type C57BL/6J mice were obtained from The Jackson Laboratory. BSDL–/– mice were generously provided by J.L. Breslow and E.A. Fisher (The Rockefeller University, New York, New York, USA). BSDL-null mice have been previously described (34). The Beth Israel Deaconess Medical Center Institutional Animal Care and Use Committee approved all animal care and experimental procedures.
Affinity-purified rabbit polyclonal antibodies against the human pancreatic BSDL (referred to as pAbL64, pAbL32, and pAbantipeptide) were prepared at INSERM UMR-777 (30) and shown to cross-react with mBSDL. Irrelevant rabbit immunoglobulins were obtained from preimmune rabbit sera and purified by protein A–Sepharose affinity chromatography. A blocking monoclonal anti-human CXCR4 antibody (clone 44716.111) and CXCR4 inhibitor (AMD3100) were from Sigma-Aldrich. Rat monoclonal anti-mouse CD41 antibody (clone MWReg30), rat monoclonal anti-mouse P selectin antibody (clone RB 40.34), inhibitory mouse monoclonal anti-human CXCR4 antibody (clone 12G5), and PAC-1 FITC-labeled antibody directed against activated αIIbβ3 were from BD Biosciences — Pharmingen. Mouse anti-human fibrin II β-chain antibody (clone NYBT2G1) was from Accurate Chemical and Scientific Corp. Fab fragments from the anti-CD41 antibody were generated using the ImmunoPure Fab Preparation Kit (Pierce Biotechnology) and then conjugated to Alexa Fluor 647 according to the manufacturer’s instructions (Invitrogen). Anti-fibrin antibody was conjugated to Alexa Fluor 488. Human α-thrombin was from Hematologic Technologies Inc. A3P5P, MRS 2395 (P2Y12 antagonists), MRS 2179 (P2Y1 antagonist), ADP, and SDF-1 were purchased from Sigma-Aldrich. AYPGKF peptide (TRAP-4) was from Anaspec. SFLLRN peptide (TRAP-1) and a peptide with the sequence of the V3-like loop of BSDL (17) were obtained from Eurogentec. The sequence-related peptide analogs of the V3-like loop (V3Lscr and V3Lsal) were generated by solid-phase peptide synthesis and their structures confirmed by automated Edman degradation on an ABI 891 Prosequencer (Applied Biosystems) and by mass spectroscopy.
HUVECs were isolated as described previously (44) and were obtained from F. Dignat-George (UMR-608 INSERM, Marseille, France). HUVECs were grown to confluence in EGM-2 medium and used at passages II–IV. HEK293t and CXCR4-transfected HEK293t cell lines were a generous gift from M. Biard-Piechaczyk (CNRS UMR 5121, Montpellier, France). HEK 293t-CXCR4 cells were maintained in DMEM medium supplemented with 10% FCS, penicillin (100 U/ml), streptomycin (100 μg/ml), zeomycin (0.25 mg/ml). HEK293t cell lines were cultured in DMEM without zeomycin. All these cells lines were kept at 37°C in a humidified atmosphere of 95% O2 and 5% CO2.
Human platelets were obtained from healthy volunteers who had not taken anti-platelet medications for 2 weeks prior to blood donation. Blood was drawn from healthy volunteers who provided informed consent. The procedure was performed according to a protocol approved by the Institutional Review Board of the Beth Israel Deaconess Medical Center. Platelets were separated from freshly drawn blood by centrifugation and washed twice in CGS (13 mM trisodium citrate, 30 mM dextrose, and 120 mM NaCl, pH 7.0) in the presence of 0.02 U/ml apyrase (Sigma-Aldrich) and 500 nM PGI2 (Calbiochem) and once in ETS buffer (1 mM EDTA, 10 mM Tris-HCl, and 154 NaCl, pH 7.4) as described previously (45). Washed platelets were resuspended at a concentration of 3 × 108 platelets/ml in Tyrode buffer (138 mM NaCl, 2.9 mM KCl, 12 mM NaHCO3, 5.5 mM glucose, 1.8 mM CaCl2, and 0.4 mM MgCl2, pH 7.4) containing 0.2% BSA (Sigma-Aldrich). Mouse platelets were prepared similarly and were resuspended at a concentration of 1 × 108 platelets/ml in Tyrode buffer containing 0.2% BSA. For the experiments monitoring calcium mobilization, mouse and human platelets were incubated with 3 μM fura-2/AM (Invitrogen) for 40 minutes in the dark at 37°C, pelleted, and resuspended in Tyrode buffer before use as previously described (38).
HUVECs were seeded into a 24-well plate at 0.45 × 105 cells per well and maintained in EGM-2 medium. At 80% of confluence, HUVECs were incubated in medium 199 supplemented with inactivated FCS (5%) for 24 hours. BSDL in the presence and absence of thrombin in fresh medium 199 was added to HUVECs for 6 hours. Medium samples were centrifuged at 500 g for 5 minutes and stored at –80°C until assay. The concentration of keto-PGF1α, a metabolite of PGI2, was assayed in medium samples by enzymatic immunoassay (Cayman Chemical Co.).
HUVECs were treated as described above. The concentration of nitric oxide was assayed in medium sample by colorimetric assay (Calbiochem).
SDS-PAGE was performed on gels of polyacrylamide (7.5 % acrylamide) and 0.1 % sodium dodecyl sulfate as previously described (30).
HUVECs and HEK293t and HEK293t-CXCR4 cells were grown to 80% confluence on microscope coverslips and washed 3 times with PBS buffer and fixed with 3% (vol/vol) paraformaldehyde for 20 minutes. The excess of paraformaldehyde was eliminated by washing the slides in 1 M glycine (pH 8.5). Between each step, cells were exhaustively rinsed with PBS. Cells were prepared for immunofluorescence as already described (42) using appropriate primary antibodies and conjugates. In some cases, resting or thrombin activated platelets (0.1 U/ml) were fixed with paraformaldehyde (3%) or glutaraldehyde (0.1%) for 30 minutes. Platelets were then washed 3 times in CGS buffer and incubated for 2 hours with appropriated antibodies.
Flow cytometry experiments were performed on 1.5 × 107 washed human platelets. Resting or thrombin-activated (0.5 U/ml) platelets were incubated with or without hBSDL (5 μg) or V3-like loop peptides (1 μg) for 5 minutes, in the presence of 1 mM CaCl2. For BSDL detection, platelets were permeabilized as indicated by addition of 0.01% saponin in all the buffers. Platelets were then incubated with antibodies against P selectin or activated αIIbβ3 or with the antibody pAbL32 coupled to Alexa Fluor 488 and directed against hBSDL. A secondary FITC-conjugated antibody was added when required. Expression of activated αIIbβ3, P selectin, or BSDL on the surface of and in resting and activated platelets was analyzed using a BD FACSCalibur flow cytometer.
Washed human platelets (3 × 108/ml) were stirred at 37°C for 10 minutes in a 4-channel aggregometer (Chrono-Log Corp.). hBSDL (5 μg), V3-like peptides (1 μg), or SDF-1 (100 μM) were added to platelets after activation with thrombin (0.15–1 U/ml), TRAP-1 (10–15 μM), TRAP-4 (100 μM), or ADP (2.5–5 μM). In some experiments, hirudin (20 μg/ml), apyrase (0.4 U), A3P5P (34 μM), MRS2395 (10 μM), or MRS2179 (100 μM) was added. The extent of platelet aggregation was defined as the percentage change in optical density.
Thrombin-activated (1 U/ml) or resting platelets were incubated with hBSDL (5 μg) for 5 minutes and the platelets transferred to glass coverslips. After 5, 20, or 40 minutes, platelet spreading was stopped by the addition of paraformaldehyde (2%) for 20 minutes. The coverslips were washed with PBS and platelets bound to the coverslips were detected with Alexa Fluor 647–conjugated anti-mouse CD41 Fab fragment. Platelets attached to coverslips were washed 3 times with PBS to remove the excess of Alexa Fluor 647–conjugated anti-mouse CD41 Fab fragment. Coverslips were mounted on microscope slides, and fluorescent images were recorded and analyzed with Slidebook software (Intelligent Imaging Innovations).
Fura-2–loaded platelets (1 × 108 platelets/ml) were preincubated and stirred in a cuvette in a Perkin Elmer LS45 Fluorescence Spectrometer for 1 minute at 37°C with 2 mM of CaCl2; then 0.1 U of thrombin, 0.1 μg of V3-like loop peptide, or 0.5 μg of hBSDL was added and the fluorescence change recorded. The fluorescence emission following excitation at 340 nm and 380 nm was recorded at 510 nm (36, 46).
Intravital videomicroscopy of the cremaster muscle microcirculation was performed as previously described (29). Mice were preanesthetized with intraperitoneal ketamine (125 mg/kg; Abbott Laboratories), xylazine (12.5 mg/kg; Phoenix Pharmaceuticals), and atropine (0.25 mg/kg; American Pharmaceutical Partners). A tracheal tube was inserted and the mouse maintained at 37°C on a thermo-controlled rodent blanket. To maintain anesthesia, Nembutal (Abbott Laboratories) was administered through a cannulas placed in the jugular vein. After the scrotum was incised, the testicle and surrounding cremaster muscle were exteriorized onto an intravital microscopy tray. The cremaster preparation was superfused with thermo-controlled (36°C) and aerated (95% N2, 5% CO2) bicarbonate-buffered saline throughout the experiment. Microvessel data were obtained using an Olympus AX microscope with a 60× 0.9 NA water immersion objective. The fluorescence microscopy system has previously been described (47). Digital images were captured with a Cooke Sensicam CCD camera in 640 × 480–pixel format.
Antibodies or exogenously labeled mouse platelets (250 × 106 to 300 × 106) were infused through the jugular vein into the circulation of an anesthetized mouse. Vessel wall injury was induced with a nitrogen dye laser (Micropoint; Photonics Instruments) focused through the microscope objective, parfocal with the focal plane and aimed at the vessel wall (35). Typically 1 or 2 pulses were required to induce vessel wall injury. For the experiments involving injection through the jugular vein of antibodies against the endogenous BSDL (pAbL32, pAbL64, pAbantipeptide), against CD41, or against fibrin in the presence or absence of CXCR4 inhibitor (AMD3100), 3 or 4 mice were studied and a maximum of 10 thrombi induced per mouse. For the in vivo calcium experiments, mouse platelets loaded with fura-2 were injected in a mouse through the jugular vein. Six thrombi were generated per mouse over a time course of about 45 minutes. For this set of experiments, 3 mice were studied. In all experiments new thrombi were formed upstream of earlier thrombi to avoid any contribution from thrombi generated earlier. There were no characteristic trends in thrombus size or thrombus composition in sequential thrombi generated in a single mouse during an experiment. Image analysis was performed using Slidebook. Fluorescence data were captured digitally at up to 50 frames per second and analyzed as previously described (35).
Confocal intravital microscopy was performed as previously described (47), except that the rate of image acquisition was increased. A modified Lambda DG-4 (Sutter) was used to generate monochromatic light from a 3-line argon-krypton laser. For image analysis, the mean and maximal background intravessel fluorescence after excitation at 488 and 647 nm was defined as the average of the mean and maximal voxel fluorescence intensity in 20 neighboring sections of the vessel prior to laser-induced injury. This value was subtracted from the fluorescence signal.
Mouse tail bleeding times were determined as previously described (48). The investigator was blinded to the genotype of the mice. Briefly, a 1- to 3-mm portion of the distal tail was removed from a 6- to 8-week-old mouse, the tail was immersed in isotonic saline (37°C), and the time to complete cessation of blood flow recorded. The bleeding time was monitored for a maximum of 10 minutes.
The aggregation and spreading data were expressed as mean ± SD. Significance was determined by paired 2-tailed Student’s t test for the in vitro experiments and Wilcoxon’s rank-sum test for the in vivo experiments. The difference was considered significant at P < 0.05.
The authors are indebted to E.A. Fisher and J.L. Breslow (The Rockefeller University) for providing the BSDL-null mice. The authors are grateful to M. Jacob for the synthesis of V3Lscr and V3Lsal peptides, Nadine Bruneau for review of the original data on apolipoprotein-bound BSDL, Marie Christine Alessi for the use of the aggregometer, and Françoise Dignat-George for the gift of HUVECs. This work was supported by grants from the NIH and by institutional funding from INSERM and the Université de la Méditerranée.
Nonstandard abbreviations used: BSDL, bile salt–dependent lipase; CXCR4, CXC chemokine receptor 4; FAPP, fetoacinar pancreatic protein; hBSDL, human BSDL; mBSDL, mouse BSDL; SDF-1, stromal cell–derived factor–1; TRAP-1, thrombin receptor activation peptide 1.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 117:3708–3719 (2007). doi:10.1172/JCI32655